Patents by Inventor Patrick M. Hughes

Patrick M. Hughes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10406168
    Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: September 10, 2019
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Michele Boix, Christian Sarrazin, Marina Do
  • Patent number: 10398707
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: September 3, 2019
    Assignee: Allergan, Inc.
    Inventor: Patrick M. Hughes
  • Patent number: 10363214
    Abstract: Compositions and methods for treating dry age related macular degeneration (dry AMO) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: July 30, 2019
    Assignee: Allergan, Inc.
    Inventors: Scott M. Whitcup, Michael R. Robinson, Wendy M. Blanda, Patrick M. Hughes, James A. Burke
  • Patent number: 10328086
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: June 25, 2019
    Assignee: Allergan, Inc.
    Inventor: Patrick M. Hughes
  • Publication number: 20190167858
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
    Type: Application
    Filed: February 11, 2019
    Publication date: June 6, 2019
    Inventors: Glenn T. Huang, Brittany Jackson, James A. Burke, Ton Lin, Patrick M. Hughes, Larry A. Wheeler, Rosy Sheng Donn
  • Patent number: 10201641
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: February 12, 2019
    Assignee: Allergan, Inc.
    Inventors: Glenn T. Huang, Brittany Jackson, James A. Burke, Ton Lin, Patrick M. Hughes, Larry A. Wheeler, Rosy Sheng Donn
  • Publication number: 20190038551
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol.
    Type: Application
    Filed: September 10, 2018
    Publication date: February 7, 2019
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Publication number: 20190022195
    Abstract: Pharmaceutical formulations comprising a clostridial derivative and a permeabilizing agent for intravesical instillation are disclosed.
    Type: Application
    Filed: April 16, 2018
    Publication date: January 24, 2019
    Inventors: Eric A. Forssen, Patrick M. Hughes, David C. Rupp, Terrence Hunt, Gary Shimizu, Joseph Francis, Ron S. Broide, Ester Fernandez-Salas
  • Publication number: 20190000935
    Abstract: A biodegradable film comprising a therapeutically effective amount of a Clostridial neurotoxin is described. Methods for treating rhinitis and for treating a symptom of rhinitis by administering the biodegradable film to the nasal cavity are also described.
    Type: Application
    Filed: June 28, 2018
    Publication date: January 3, 2019
    Inventors: Mitchell F. Brin, Patrick M. Hughes, Guang Wei Lu
  • Patent number: 10076492
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: September 18, 2018
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Publication number: 20180236215
    Abstract: Microneedle arrays for introducing an active ingredient through a skin surface of a subject can include a base layer, a plurality of microneedles projecting from the base layer, and an active ingredient. Each of the microneedles comprises an elongate body having a proximal portion and a distal portion, in which the proximal portion is attached to the base layer. Each of the microneedles comprises at least one dissolvable polymer. The active ingredient is incorporated in the elongate body, and the active ingredient is present only in the distal portion and at least internally in the distal portion.
    Type: Application
    Filed: February 16, 2018
    Publication date: August 23, 2018
    Inventors: Futian LIU, Xiaojie YU, Lance E. STEWARD, Guang Wei LU, Patrick M. HUGHES, Sheshadri NEERVANNAN
  • Publication number: 20180207174
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce at least one symptom of an ocular condition, such as glaucoma.
    Type: Application
    Filed: August 31, 2017
    Publication date: July 26, 2018
    Inventor: Patrick M. Hughes
  • Publication number: 20180161342
    Abstract: Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
    Type: Application
    Filed: February 12, 2018
    Publication date: June 14, 2018
    Inventors: Patrick M. Hughes, Jie Shen, Michael R. Robinson, David F. Woodward, Robert M. Burk, Hui Liu, Jinping Wan, Chandrasekar Durairaj, Gyorgy F. Ambrus, Ke Wu, Danny T. Dinh
  • Patent number: 9943576
    Abstract: Pharmaceutical formulations comprising a clostridial derivative and a permeabilizing agent for intravesical instillation are disclosed.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: April 17, 2018
    Assignee: Allergan, Inc.
    Inventors: Eric A. Forssen, Patrick M. Hughes, David C. Rupp, Terrence Hunt, Gary Shimizu, Joseph Francis, Ron S. Broide, Ester Fernandez-Salas
  • Patent number: 9889142
    Abstract: Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: February 13, 2018
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Jie Shen, Michael R. Robinson, David F. Woodward, Robert M. Burk, Hui Liu, Jinping Wan, Chandrasekar Durairaj, Gyorgy F. Ambrus, Ke Wu, Danny T. Dinh
  • Publication number: 20180021348
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The Implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Application
    Filed: October 2, 2017
    Publication date: January 25, 2018
    Inventor: Patrick M. Hughes
  • Patent number: 9775846
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: October 3, 2017
    Assignee: Allergan, Inc.
    Inventor: Patrick M. Hughes
  • Publication number: 20170266201
    Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at one symptom of an ocular condition, such as glaucoma.
    Type: Application
    Filed: June 5, 2017
    Publication date: September 21, 2017
    Inventors: Patrick M. Hughes, Michele Boix, Christian Sarrazin, Marina Do
  • Patent number: 9750751
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: September 5, 2017
    Assignee: Allergan, Inc.
    Inventor: Patrick M. Hughes
  • Publication number: 20170216414
    Abstract: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.
    Type: Application
    Filed: April 17, 2017
    Publication date: August 3, 2017
    Inventors: Ahmet Tezel, Wendy M. Blanda, Patrick M. Hughes, Scott M. Whitcup, James N. Chang, Michael R. Robinson